Monday, August 2, 2010

MADRAS CEMENTS = FIRST QUARTER (Q1 FY 2011) = RESULTS = LOWER SALES & PROFITS



MADRAS CEMENTS LIMITED
Q1 FY 2011 RESULTS
COMPARISON
NON CONSOLIDATED FIGURES

Madras Cements has reported fall in sales and profits both in the Q1 FY2011 compared to the corresponding quarter of q1 FY2010 – and also proportionately (Q1 FY2011 x 4) compared to FY2010.
Net Sales is Rs.697 Cr – DOWN by 9.3% compared to corresponding Qtr of Q1 FY10 (Rs.768 Cr) – and proportionately down by 0.4% compared to FY 2010.(Rs.2801 Cr).
Profit from Operations        is Rs.142 Cr – DOWN by 42.2% from Q1 FY2010 (Rs.246 Cr) – and proportionately down by 15.7% from FY2010 (Rs.674 Cr).
 Net Profit     is Rs.73 Cr – DOWN by a huge 47.6% from Q1 FY2010 (Rs.138 Cr)  - and proportionately down by 17.9% from FY2010 (Rs.354 Cr). This , as we can see from the figures below, is due to (i) Fall in Net Sales income and (ii) a sizeable increase in Expenditure.
Basic EPS       is Rs.3 against Rs.6 in Q1 FY2010 and  Rs.15 in the whole of FY2010. The face value is Rs.1. Whether Madras cements can achieve last year’s EPS of Rs.15 is to be seen. At present rate, annual EPS can be around Rs.12.
MARKET PRICE : The market price is around Rs.100. In view of the lower results, the further price movements need to be watched.
EXPANDING CEMENT CAPACITIES : Most cement companies are expanding their Plants and new companies are seriously thinking of joining the Fray by starting new plants. Thus the growth in demand is being more than neutralized by supply. Hence, whether sales of all cement companies will register fall in coming quarters is to be seen. Also, whether this may lead to pricing pressures is a factor to be considered. The cement Industry needs to consider these factors seriously. While infrastructure Industry expansion will no doubt add to demand – the possibility for supply to outstrip demand cannot be overlooked. Madras cements is of course, one of the more efficient and highly profitable Units.

RESULTS IN FIGURES :

Jun-10
Jun-09
Dif%1
Dif%2
Net Sales
69724
76836
-9.3
280089
-0.4
Other Otg Income
317
124
155.6
1291
-1.8
SIT & WIP
-1822
279
-753
-400
1722
Raw Materials
27616
25342
9
99868
10.6
Employees Cost
3939
3273
20.3
13733
14.7
Depreciation
5373
4506
19.2
19609
9.6
Other Exp
20744
19001
9.2
81195
2.2
Total Exp
55850
52401
6.6
214005
4.4
Profit.Operations
14191
24559
-42.2
67375
-15.7
Other Income
179
158
13.3
746
-4
P B I&EI
14370
24717
-41.9
68121
-15.6
Interest
3500
3750
-6.7
15088
-7.2
P A I B B EI
10870
20967
-48.2
53033
-18
PBT
10870
20967
-48.2
53033
-18
Tax expense
3610
7125
-49.3
17676
-18.3
PAT
7260
13842
-47.6
35357
-17.9
Net Profit
7260
13842
-47.6
35368
-17.9
Dividend (%)
-
-

200
Face Value
1
1
0
1
Paid Up Equity
2380
2380
0
2380
Reserves
-
-

153435
Basic EPS
3
6
-50
15
-20
Public holding (%)
58
58
0
58


ANNOUNCEMENTS
TO THE EXCHANGE

02-08-2010        Madras Cements Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 69724 lacs for quarter ending on 30-JUN-2010 against Rs. 76836 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7260 lacs for the quarter ending on 30-JUN-2010 against Rs. 13842 lacs for the quarter ending on 30-JUN-2009.     -
24-05-2010        Madras Cements Limited has informed the Exchange that the company has announced the book closure from July 27, 2010 to August 02, 2010 (Both days inclusive) for the purpose of payment of final dividend of Rs. 0.50/- per share of Rs. 1/- each. Further, the Annual General Meeting is scheduled to be held on August 02, 2010. -
24-05-2010        Madras Cements Limited has informed the Exchange that the Board of Directors at its Meeting held on May 24, 2010 has approved payment of final dividend of Rs. 0.50 per share for the year 2009-10. Together with the interim dividend of Rs. 1.50 per share paid already, the total dividend for the year 2009-10 is Rs. 2.00 per share.
24-05-2010        Madras Cements Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 280089 lacs for year ending on 31-MAR-2010 against Rs. 253040 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 35368 lacs for the year ending on 31-MAR-2010 against Rs. 36352 lacs for the year ending on 31-MAR-2009.
28-01-2010        Madras Cements Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 60710 lacs for quarter ending on 31-DEC-2009 against Rs. 60916 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 1601 lacs for the quarter ending on 31-DEC-2009 against Rs. 6273 lacs for the quarter ending on 31-DEC-2008.
31-10-2009        Madras Cements Ltd. has informed the Exchange that the Board of Directors of the Company at their meeting held on October 27, 2009, have decided to divest the shares in a wholly owned subsidiary, viz. MADRAS SUGARS LIMITED, which was incorporated for the purpose of carrying out sugar business. The paid-up capital of Madras Sugars Limited in Rs. 10 lakhs.

 *  *  *    E N D    *  *  *

GlaxoSmithKline Consumer Healthcare = Q2 /E JUNE 2010 = RESULTS = GOOD IMPROVEMENT



GlaxoSmithKline Consumer Healthcare Limited
NSE SYMBOL :GSKCONS
Q2 (APR – JUN) OF  
CY2010 (JAN TO DEC)
RESULTS COMPARISON

GlaxoSmithKline consumer Health care Limited has declared reasonably good results for the 2nd quarter ending June,2010. The figures are compared below with the previous or first quarter (ending March 2010) and the corresponding qtr (ending June 2009). The Q1+Q2 figures upto June 2010 are multiplied by 2 for estimating the CY2010 figures (Q1+Q2 of CY2010 Known figures x 2 = full year of 2010) and these are compared with  the full previous year of CY2009.

Net Sales  at Rs.537 cr is DOWN by 17.1% compared to previous qtr( Rs.648 Cr)  - but up by 14.6% compared to corresponding qtr (Rs.469 Cr) .Q1+Q2 is up proportionately by 23.4 % compared to CY2009 (Rs.1922 Cr).
Profit  from Operations       is Rs.95 cr – down by 31.5% from previous qtr (Rs.139 Cr) – but up by 17.8% from Corresponding Qtr (Rs.81 Cr) and Q1_Q2 is up proportionately by 41.4% compared to CY2009(Rs.331 Cr).
Net Profit for Q2 (Rs.72Cr) is down by 25.4% from previous qtr (Rs.96 Cr) – but up by a good 30% from corresponding qtr of FY2009 (Rs.55 Cr) and Q1+Q2 figures are proportionately up by 44.3% from CY2009 (Rs.233 Cr).
Basic EPS at Rs.17.06      on the face Value of Rs.10 – is down by 25.4% from previous qtr (Rs.22.86)  - but is up by 30% from corresponding qtr (Rs.13.12) . The Q1+Q2 EPS is higher proportionately by 44.2% from CY2009 EPS of Rs.55.35.
PE RATIO : On the above basis, the annual EPS for current year is likely to be around Rs.80. Current Market price is Rs.1770. on this, the PE Ratio works out to 22.12.
RESULTS IN FIGURES :

Jun-10
Mar-10
dif%1
Jun-09
dif%2
dif%3
Net Sales
53735
64843
-17.1
46872
14.6
192150
23.4
Other OptgIncome
1515
1561
-2.9
1681
-9.9
6255
-1.6
SIT & WIP
-1202
4952
-124
-443
171

Raw Materials
19347
18554
4.3
16267
18.9

Traded Goods
2106
2106
0
1399
50.5
6523
29.1
Employees Cost
5889
5163
14.1
5234
12.5
20070
10.1
Depreciation
928
957
-3
1053
-12
4202
-10
Other Exp
18656
20763
-10.1
16956
10
69936
12.7
Total Exp
45724
52495
-12.9
40466
13
165269
18.9
Profit .Operations
9526
13909
-31.5
8087
17.8
33136
41.4
Other Income
1291
797
62
603
114
2677
56
PB I & EI
10817
14706
-26.4
8690
24.5
35813
42.5
Interest
62
57
8.8
105
-41
427
-44
P A I B B EI
10755
14649
-26.6
8585
25.3
35386
43.6
P B T
10755
14649
-26.6
8585
25.3
35386
43.6
Tax expense
3580
5033
-28.9
3066
16.8
12108
42.3
P A T
7175
9616
-25.4
5519
30
23278
44.3
Net Profit
7175
9616
-25.4
5519
30
23278
44.3
Dividend%
-
-

-

-
Face Value.Rs
10
10
0
10
0
10
Paid Up Equity
4206
4206
0
4206
0
4206
Reserves
-
-

-

-
Basic EPS
17.06
22.86
-25.4
13.12
30
55.35
44.2
Public holding%
56.84
56.84
0
56.84
0
56.84




ANNOUNCEMENTS TO
THE EXCHANGE

02-08-2010        GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 53735 lacs for quarter ending on 30-JUN-2010 against Rs. 46872 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7175 lacs for the quarter ending on 30-JUN-2010 against Rs. 5519 lacs for the quarter ending on 30-JUN-2009.        -
23-04-2010        GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 64843 lacs for quarter ending on 31-MAR-2010 against Rs. 53937 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 9616 lacs for the quarter ending on 31-MAR-2010 against Rs. 8389 lacs for the quarter ending on 31-MAR-2009.        -
25-01-2010        Glaxosmithkline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on January 25, 2010 has recommended a Final Dividend at the rate of Rs.18 per equity share of Rs.10 each. Further, the Annual General Meeting is scheduled to be held on April 23, 2010.
25-01-2010        GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 192150 lacs for year ending on 31-DEC-2009 against Rs. 154278 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 23278 lacs for the year ending on 31-DEC-2009 against Rs. 18833 lacs for the year ending on 31-DEC-2008.

*  *  *    E N D   *  *  *